Header: Clinical Trials for Mesothelioma Patients: Pazopanib Study Description
Read the study description about a current clinical trial being conducted to study the effects of Pazopanib for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Study Description
Phase, Type and Design: Phase II Interventional Study; Treatment, Open Label;
Primary Outcome Measure: Proportion of patients who are progression-free at 6 months
Secondary Outcome Measures: Response to treatment; Overall survival; Progression-free survival; Duration of response; Time to treatment failure; Toxicity; Tumor markers of angiogenesis
Requisite Conditions: Malignant Mesothelioma
Interventions:
Drug: Pazopanib hydrochloride
Procedures: antiangiogenesis therapy; diagnostic procedure; laboratory biomarker analysis; protein tyrosine kinase inhibitor therapy
Recruitment InformationRecruitment Status: Recruiting
Enrollment: 55
Start Date: March 2007
Courtesy of ClinicalTrials.gov.
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney
Clinical trial to study Pemetrexed drug on mesothelioma patients